Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1/2 study of ECI830 alone and with ribociclib plus endocrine therapy in advanced HR-positive/HER2-negative breast cancer and CCNE1-amplified solid tumors
MOH_2025-03-04_013953Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ECI830, ribociclib and fulvestrant in breast cancer, ovarian cancer, gastric adenocarcinoma and 2 more (6 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability and Contribution of ECI830 in combination therapy. Started Mar 2025; status: recruiting.
02
Drugs
ECI830ribociclibfulvestrant
03
Conditions
breast cancerovarian cancergastric adenocarcinomaesophageal adenocarcinoma (EAC)Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2025-03-04_013953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-04_013953.